🔗 Permalink

Inventor profile of:

Michaela KNEISSEL

City:

Basel

Country:

Switzerland

Published Applications:

Last publication date:

2025-04-17

Top Assignees for applications by Michaela KNEISSEL

The entities that hold a legal rights for patent applications filed by inventor KNEISSEL Michaela:

NOVARTIS AG 8 Basel, Switzerland
MEREO BIOPHARMA 3 LIMITED 8 London, United Kingdom

Recent patent applications by KNEISSEL Michaela

Michaela KNEISSEL from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-04-17

US20250122273A1

Chemistry; metallurgy

USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA

#2 | 2024-12-05

US20240400666A1

Chemistry; metallurgy

USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA

#3 | 2024-12-05

US20240398798A1

Human necessities

FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS

#4 | 2023-11-16

US20230365669A1

Chemistry; metallurgy

USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA

#5 | 2021-10-07

US20210308132A1

Human necessities

FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS

#6 | 2021-08-19

US20210253687A1

Chemistry; metallurgy

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

#7 | 2021-08-19

US20210253684A1

Chemistry; metallurgy

USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA

#8 | 2020-06-11

US20200181271A1

Chemistry; metallurgy

METHODS FOR PREVENTING AND TREATING URINARY INCONTINENCE

#9 | 2020-06-11

US20200179509A1

Human necessities

USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA

#10 | 2020-04-23

US20200123242A1

Chemistry; metallurgy

USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA

#11 | 2019-10-31

US20190330322A1

Chemistry; metallurgy

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

#12 | 2017-01-12

US20170007606A1

Human necessities

FGFR inhibitor for use in the treatment of hypophosphatemic disorders

#13 | 2015-03-12

US20150072019A1

Human necessities

FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS

#14 | 2013-06-27

US20130164284A1

Human necessities

COMPOSITIONS AND METHODS TO TREAT BONE RELATED DISORDERS

#15 | 2013-05-30

US20130138221A1

Human necessities

METHODS AND COMPOSITIONS FOR IMPROVING IMPLANT OSSEOINTEGRATION

#16 | 2012-11-01

US20120276591A1

Physics

Polynucleotides encoding antibodies against sclerostin and uses therefor

#17 | 2012-09-13

US20120232011A1

Chemistry; metallurgy

Use of Rapamycin and Rapamycin Derivatives for the Treatment of Bone Loss

#18 | 2012-01-05

US20120003219A1

Human necessities

Compositions and Methods to Treat Bone Related Disorders

#19 | 2011-03-03

US20110052592A1

Physics

Compositions and methods for use for antibodies against sclerostin

#20 | 2010-02-04

US20100028335A1

Human necessities

Compositions and Methods to Treat Bone Related Disorders

#21 | 2009-09-03

US20090221503A1

Chemistry; metallurgy

USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF BONE LOSS

#22 | 2009-05-21

US20090130113A1

Physics

Compositions and methods for use for antibodies against sclerostin

#23 | 2006-08-03

US20060173033A1

Chemistry; metallurgy

Use of rapamycin and rapamycin derivatives for the treatment of bone loss

InventorID:

311417 ⎘